Breaking News Instant updates and real-time market news.

SQ

Square

$66.00

-0.35 (-0.53%)

07:26
05/13/19
05/13
07:26
05/13/19
07:26

Square organic growth could sustain 40%-plus, says Deutsche Bank

Much of the recent pressure in shares of Square has been due to worries surrounding its decelerating organic sales growth, Deutsche Bank analyst Bryan Keane tells investors in a research note. However, as the analyst breaks out the key Subscription & Services-based revenue components and adds in the potential Eventbrite deal to his new upside scenario model, he believes Square's organic growth could actually stabilize in the second half of 2019 and potentially accelerate again in Q4. In his upside case, Keane thinks Square has the ability to deliver stable low 40% organic rates of revenue growth in the second half of 2019 and 2020. The traction of the Cash App is being underappreciated, says the analyst, who keeps a Buy rating on Square shares.

  • 01

    Aug

SQ Square
$66.00

-0.35 (-0.53%)

05/02/19
JPMS
05/02/19
NO CHANGE
Target $86
JPMS
Overweight
Square momentum continues with large EBITDA beat, says JPMorgan
Square's Q1 results were highlighted by the largest EBITDA beat in two years on a slightly below average revenue beat, demonstrating continued momentum in ecosystem monetization at scale against a rising total addressable market, JPMorgan Tien-tsin Huang tells investors in a research note. The company's fiscal 2019 growth guidance on adjusted revenue was taken up beyond the beat to 43% from 41%, while EBITDA was reaffirmed as expected to allow for reinvestment of upside, says the analyst. He thinks this is prudent given Square's momentum in product usage "against lots of competition." Huang maintains an Overweight rating on the shares with an $86 price target.
05/02/19
ADAM
05/02/19
NO CHANGE
Target $88
ADAM
Buy
Square's Q2 results were 'solid,' says Canaccord
Canaccord analyst Michael Graham backed a Buy rating and $88 price target on Square following the company's "solid" Q2 results, with revenue slightly ahead of consensus and EBITDA sharply ahead. Graham tells investors in a research note that while there may be short-term stock headwinds from Square's results he remains constructive regarding the opportunity to layer in new, high margin revenue streams.
05/02/19
RHCO
05/02/19
NO CHANGE
Target $65
RHCO
Hold
Square price target lowered to $65 from $75 at SunTrust
SunTrust analyst Andrew Jeffrey lowered his price target on Square to $65 to reflect its below-consensus Q2 guidance, saying that while he is positive on the company's above-average organic revenue and EBITDA growth, a "significant deceleration" may be coming. The analyst cites "robust competition in new vertical markets" that will demand Square to boost its investment levels on a structural basis and also warns that margin growth may slow as the company goes after larger retailer customers. Jeffrey keeps his Hold rating on Square.
05/03/19
BMOC
05/03/19
NO CHANGE
Target $90
BMOC
Market Perform
Square price target lowered to $90 from $98 at BMO Capital
BMO Capital analyst James Fotheringham lowered his price target on Square (SQ) to $90 and kept his Market Perform rating, saying that while the company's Q1 results topped consensus thanks to higher Subscription and Services revenue, its gross payment volume was lower than expected and marks a more critical "indicator of sustainable growth." The analyst sees better investment opportunities among his covered financial technology stocks in companies like Visa (V) and Global Payments (GPN).

TODAY'S FREE FLY STORIES

SILK

Silk Road Medical

$40.85

0.28 (0.69%)

07:44
08/20/19
08/20
07:44
08/20/19
07:44
Initiation
Silk Road Medical initiated  »

Silk Road Medical…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

IQ

iQIYI

$18.10

1.02 (5.97%)

07:42
08/20/19
08/20
07:42
08/20/19
07:42
Downgrade
iQIYI rating change  »

iQIYI downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SRPT

Sarepta

$120.16

-4.81 (-3.85%)

07:41
08/20/19
08/20
07:41
08/20/19
07:41
Recommendations
Sarepta analyst commentary  »

Sarepta price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNET

ChinaNet Online

$1.50

0.135 (9.89%)

07:41
08/20/19
08/20
07:41
08/20/19
07:41
Hot Stocks
ChinaNet CEO says will continue to integrate blockchain, AI tech into products »

CEO Handong Cheng,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EL

Estee Lauder

$201.74

22.48 (12.54%)

07:37
08/20/19
08/20
07:37
08/20/19
07:37
Recommendations
Estee Lauder analyst commentary  »

Estee Lauder price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

VVUS

VIVUS

$3.46

-0.02 (-0.57%)

07:36
08/20/19
08/20
07:36
08/20/19
07:36
Hot Stocks
VIVUS says study shows addition of Qsymia to LSG surgery improved weight loss »

VIVUS announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPLK

Splunk

$125.55

0.73 (0.58%)

07:36
08/20/19
08/20
07:36
08/20/19
07:36
Recommendations
Splunk analyst commentary  »

Splunk price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

  • 28

    Aug

  • 15

    Oct

TPIC

TPI Composites

$17.49

-0.2 (-1.13%)

07:35
08/20/19
08/20
07:35
08/20/19
07:35
Upgrade
TPI Composites rating change  »

TPI Composites upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

PVTL

Pivotal Software

$13.85

-0.16 (-1.14%)

07:35
08/20/19
08/20
07:35
08/20/19
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Sep

07:35
08/20/19
08/20
07:35
08/20/19
07:35
General news
Treasury Market Outlook: Treasuries are back in rally mode »

Treasury Market Outlook:…

DOW

Dow Inc.

$45.58

1.09 (2.45%)

07:34
08/20/19
08/20
07:34
08/20/19
07:34
Hot Stocks
Dow Inc. to retrofit Louisiana cracker with FCDh technology to produce propylene »

Dow announced it will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 24

    Oct

LULU

Lululemon

$178.63

0.83 (0.47%)

07:34
08/20/19
08/20
07:34
08/20/19
07:34
Recommendations
Lululemon analyst commentary  »

Lululemon earnings and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

EVER

EverQuote

$22.18

0.88 (4.13%)

07:34
08/20/19
08/20
07:34
08/20/19
07:34
Recommendations
EverQuote analyst commentary  »

EverQuote price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITRI

Itron

$70.02

0.3 (0.43%)

07:33
08/20/19
08/20
07:33
08/20/19
07:33
Downgrade
Itron rating change  »

Itron downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

BIIB

Biogen

$235.61

4.05 (1.75%)

, NVTA

Invitae

$25.78

0.6 (2.38%)

07:32
08/20/19
08/20
07:32
08/20/19
07:32
Hot Stocks
Biogen, Invitae announce availability of SMA STAT test »

Biogen (BIIB) and Invitae…

BIIB

Biogen

$235.61

4.05 (1.75%)

NVTA

Invitae

$25.78

0.6 (2.38%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

MBRX

Moleculin Biotech

$1.15

0.07 (6.48%)

07:32
08/20/19
08/20
07:32
08/20/19
07:32
Hot Stocks
Moleculin Biotech receives Emory University CTRC approval for WP1066 trial »

Moleculin Biotech…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$74.86

1.6 (2.18%)

07:31
08/20/19
08/20
07:31
08/20/19
07:31
Hot Stocks
Qualcomm, LGE enter new global patent license agreement »

Qualcomm announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Sep

  • 06

    Nov

CRM

Salesforce

$143.66

-0.23 (-0.16%)

07:31
08/20/19
08/20
07:31
08/20/19
07:31
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Aug

  • 28

    Aug

  • 28

    Aug

  • 12

    Dec

  • 16

    Dec

HAIN

Hain Celestial

$21.88

0.14 (0.64%)

07:28
08/20/19
08/20
07:28
08/20/19
07:28
Downgrade
Hain Celestial rating change  »

Hain Celestial downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

  • 15

    Sep

VNO

Vornado

$61.34

0.14 (0.23%)

07:26
08/20/19
08/20
07:26
08/20/19
07:26
Downgrade
Vornado rating change  »

Vornado downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Oct

MKC

McCormick

$168.53

-1.585 (-0.93%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Downgrade
McCormick rating change  »

McCormick downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LVS

Las Vegas Sands

$54.67

2.28 (4.35%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Downgrade
Las Vegas Sands rating change  »

Las Vegas Sands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HD

Home Depot

$207.98

4.335 (2.13%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Recommendations
Home Depot analyst commentary  »

Home Depot Q2 results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

CSCO

Cisco

$48.50

1.54 (3.28%)

07:25
08/20/19
08/20
07:25
08/20/19
07:25
Recommendations
Cisco analyst commentary  »

Cisco 'sum of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 10

    Oct

  • 13

    Nov

RGNX

Regenxbio

$37.50

0.27 (0.73%)

, ADVM

Adverum Biotechnologies

$12.91

-0.5 (-3.73%)

07:24
08/20/19
08/20
07:24
08/20/19
07:24
Upgrade
Regenxbio, Adverum Biotechnologies rating change  »

Regenxbio upgraded to…

RGNX

Regenxbio

$37.50

0.27 (0.73%)

ADVM

Adverum Biotechnologies

$12.91

-0.5 (-3.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Sep

  • 11

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.